Albert Agro

Albert Agro is the President and CEO of Colomba Therapeutics Inc., a US-based biotech company developing novel therapeutics in the treatment of allergy and immunology. Most recently, Albert was the CEO of Sublimity Therapeutics Ltd , where he was instrumental raising $75M in capital to support a Phase 2B study in ulcerative colitis.

Albert is also the Co-Founder of GRI Bio, a clinical-stage company in idiopathic pulmonary fibrosis. He has held executive positions at Versanum (CEO), Cynapsus (CMO), Ironshore Pharma (CMO), Trillium Therapeutics Inc (CMO), Stem Cell Therapeutics (CMO) and Transtech Pharma (EVP).

He has maintained a position as Professor, Department of Pathology and Molecular Medicine at McMaster University in Hamilton, Ontario since September 1996. He is the recipient of a Michael J. Fox Foundation Clinical Scholarship for his work in Parkinson’s disease.